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ABSTRACT
Background and aims: Anxiety and depression are common in
patients with chronic obstructive pulmonary disease (COPD).
The degree of lung function may not explain anxiety and
depression. The aim of our study was to assess the psycholog-
ical aspects of COPD, to test the BODE index (a composite
score of body mass, obstruction, dyspnea and exercise capac-
ity), and to evaluate the association between atypical cyto-
logic findings of sputum, bronchoalveolar lavage (BAL) and
the pyschological components of the disease. 
Methods: COPD was classsified according to the GOLD stages
based on forced expiratory volume in 1 second (FEV1) in 60
stable patients. The BODE index was calculated for grading
COPD. The Hospital anxiety and depression (HAD) scale was
used to appraise the anxiety and depression symptoms.
Cytologic examination of sputum and BAL samples were per-
formed in each patient. The cytologic findings were classified
as normal, mild, moderate or severe atypia. 
Results: The overall prevalance of anxiety and depression
symptoms was 41.7% and 46.7% respectively. The prevalance
of these symptoms increased with increasing BODE stages
and correlated well with the severity of atypical BAL cytology
results (p < 0.001). Dyspnea and reduced exercise capacity
were the predominant mechanisms leading to anxiety and
depression symptoms associated with COPD. 
Conclusions: We conclude that the BODE index is superior to
GOLD stratification for explaining anxiety and depression
symptoms in COPD. BAL cytologic findings, which reflect the
distal parenchymal lung structure, correlated significantly
with the presence of the anxiety and depression symptoms. 
Keywords: Anxiety, bronchoalveolar lavage, BODE index,
COPD, depression, GOLD.
RIASSUNTO 
Razionale e scopo: Ansietà e depressione sono frequenti nel
pazienti con broncopneumopatia cronica ostruttiva (BPCO). Il
semplice quadro funzionale può non spiegare adeguatamente
ansia e depressione. Scopo del nostro studio era valutare gli
aspetti psicologici della BPCO, testare il BODE index (un pun-
teggio composito che tiene conto di massa corporea, ostru-
zione, dispnea e capacità di esercizio) e valutare l’associazione
tra i rilievi patologici nella citologia di espettorato e BAL con
la componente psicologica della malattia.
Metodi: La BPCO è stata classificata secondo la stadiazione
GOLD basata sul volume espiratorio forzato in un secondo
(FEV1) in 60 pazienti stabili. L’indice BODE è stato calcolato
per dare una stima di gravità della BPCO. Per valutare i sinto-
mi di ansia e depressione è stata utilizzata la scala Hospital
anxiety and depression (HAD). In ogni paziente è stata effet-
tuata la valutazione della citologia dell’espettorato e del BAL.
I risultati della citologia sono stati classificati come normali o
con atipia lieve, moderata o grave.
Risultati: La prevalenza complessiva dei sintomi di ansietà e
depressione era rispettivamente del 41,7% e 46,7%. La preva-
lenza di questi sintomi aumentava all’incremento dello stadio
BODE e correlava con la gravità delle atipie nel reperto cito-
logico del BAL (p < 0,001). I meccanismi prevalenti che indu-
cevano ansietà e depressione in associazione con la BPCO era-
no la dispnea e la ridotta capacità di esercizio fisico.
Conclusioni: Concludiamo che l’indice BODE è più efficace
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della stratificazione GOLD nello spiegare i sintomi di depres-
sione e ansia nei BPCO. I risultati della citologia sul BAL, che
riflettono la struttura del polmone profondo, correlano signi-
ficativamente con la presenza dei sintomi di ansietà e depres-
sione.
Parole chiave: Ansia, BPCO, depressione, GOLD, indice BODE,
lavaggio broncoalveolare.    
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a
progressive disorder with substantial mortality and
morbidity. The main goals of treatment in COPD are
prevention or slowing of disease progression and
improving the quality of life [1]. COPD patients car-
ry a substantial psychological burden related to
their disease and frequently suffer from anxiety and
depression [2-5]. Anxiety and depression are risk
factors for rehospitalisation in these patients [4,6].
Irrespective of the presence of somatic diseases,
anxiety and depression themselves constitute a sub-
stantitial risk for increased mortality, although the
mechanism for this association is unknown [7,8].
The severity of pulmonary function impairment re-
lated to anxiety and depression in COPD patients
has been the subject of research but in most studies
no correlation was found between psychological
aspects of the disease and the forced expiratory vol-
ume in 1 second (FEV1) value. On the other hand,
the presence of respiratory symptoms leads to sig-
nificant anxiety or depression and dyspnea has
been shown to correlate significantly with anxiety
and depression in these patients [9,10].
Lung damage due to the inflammation of small air-
ways appears to be the primary mechanism for dys-
pnea and physical disability leading to psychiatric
comorbidities in COPD patients [2,6,8,9]. Sputum
and bronchoalveolar lavage (BAL) cytology may be
useful for identifying depression and anxiety in
these patients by revealing inflammatory and cellu-
lar changes of the lung parenchyma. The aim of our
study was to assess the psychological aspects of
COPD, evaluate the correlation of the BODE index
(a composite score of body mass, obstruction, dys-
pnea and exercise capacity) with anxiety and de-
pression symptoms, and to evaluate the association
between sputum and BAL cytology and the psycho-
logical disorders associated with COPD.
PATIENTS AND METHODS
This was a prospective cross-sectional study per-
formed at the Respiratory Diseases Department of
Cerrahpasa Medical Faculty  between January 2008
and June 2010. The study was approved by the
Institutional ethics commitee and informed consent
was obtained from all patients. Sixty adult patients
with stable COPD were included in the study.
Inclusion criteria were: COPD diagnosed according
to the Global Initiative for Obstructive Lung Disease
(GOLD) consensus, stable disease, absence of any
other chronic disease, ability to perform a 6-minute
walking test, to complete the questionnaires, and
no contraindications for bronchoscopy and BAL.
Spirometry was performed according to the
ATS/ERS recommendations with a body plethysmo-
graph unit (Zan 500, Messgeraete, Oberthulba,
Germany). Blood gases were determined from radi-
al artery samples using the Radiometer ABL800
FLEX blood gas analyzer.
The patients were stratified according to the GOLD
classification of severity. Sputum samples were ob-
tained from every patient. If the sputum sample
contained 10 or more squamous epithelial cells per
low-power (x100) magnification field then the spec-
imen was considered unsatisfactory and was dis-
carded. BAL was performed by instilling five 20 ml
aliquots of sterile saline into a subsegment of lingu-
la or middle lobe. After removal of mucus fluid the
sample was prepared for cytologic examination by
cytocentrifugation. BAL findings were evaluated by
a pathologist and a cytologist. Cytologic findings
were classified as normal, mild, intermediate or se-
vere atypia. BAL cytology was evaluated according
to the staining characteristics, cellular cohesion,
nucleus, cytoplasmic features and nucleus cyto-
plasm ratio epithelial cells, Goblet (brush border)
cells, Clara cells, neutrophils, and type I and type II
alveolar cells. Mild atypia showed pale, abundant
cytoplasm, nucleus with a fine chromatin pattern,
round or oval nucleus, and cohesive cell sheets
with a mild disruption of the nucleus cytoplasm ra-
tio. Severe atypia revealed acidophilic cytoplasm,
discohesive cells, hyperchromatic and irregular nu-
cleus, conspicuous nucleolus and a significant in-
crease in the nucleus cytoplasm ratio. Cytologic
findings that did not fit into either mild (Figure 2) or
severe (Figure 1) type were designated as intermedi-
ate atypia. The cytologic results were classified as
follows: normal = 0, mild atypia = 1, intermediate
atypia = 2, and severe atypia = 3.
The BODE index was calculated for classification of
COPD. The index score comprises body mass index
(BMI), FEV1, dyspnea grade as measured by the
Modified Medical Research Council (MMRC) scale,
and the 6-minute walking distance (6MWD)
[11,12]. The Hospital anxiety and depression (HAD)
scale was used for screening psychiatric disorders.
It has been used for screening COPD patients pre-
viously. The scale consists of seven questions relat-
ed to anxiety and depression, rated on a 4-point
scale. The test provides maximum subscale scores
of 21 for anxiety and depression, with a score of 
≥ 8 describing the presence of these symptoms
[2,3,6,13,14]. In each patient who scored ≥ 8 the
existence of anxiety and depression was investigat-
ed by a consultant psychiatrist. 
Statistical data were expressed as mean ± standard
deviation. Differences between groups were tested
with the Student’s t-test and non-parametric Mann-
Whitney test for continuous data. The chi-square
test was used for noncontinuous data. To analyze
differences of anxiety and depression scores be-
tween different stages of COPD one-way ANOVA































by the chi-square test to evaluate how well they ex-
plained anxiety and depression symptoms. Linear
regression was used for BODE components associ-
ated with the HAD scores. Statistical analysis was
performed using the SPSS 17.0 statistical package. A
p value of less than 0.05 was accepted as statistical-
ly significant.
RESULTS
Sixty stable COPD patients (males 35, mean age 66
± 11 years) participated in the study. The patient
characteristics are outlined in Table I. The number
of COPD patients in stages II to IV by GOLD classi-
fication and the mean BODE index of the patients
are shown in Table II. The BODE index ranged from
stage II to IV. The mean scores for anxiety and de-
pression were 8.2 ± 4.6 and 7.9 ± 4.3 respectively.
Twenty-five patients (41.7%) were found to have
symptoms suggestive of anxiety and 28 patients
(46.7%) had symptoms suggestive of depression. 
There was no correlation between the presence of
anxiety or depression symptoms and age, gender or
smoking level (pack/years) (Table III). Anxiety and
depression scores correlated with the BODE index
(Kτ = 0.19, p < 0.001; Kτ = 0.34, p < 0.001). The
prevalance of anxiety increased with increasing
BODE index (χ2 = 7.46, p < 0.001) but not with in-
creasing GOLD stages (χ2 = 3.72, p < 0.42). The
prevalance of depression increased with both in-
creasing BODE index and GOLD stages (χ2 =
28.54, p < 0.001; χ2 = 38.24, p < 0.001). The mean
anxiety score for GOLD stages II, III, and IV was 4.1
± 2.8, 7.4 ± 3.8 and 8.9 ± 5.1, respectively 
(p < 0.054). The mean depression score for GOLD
stages II, III, and IV was 2.1 ± 1.6, 5.8 ± 4.2 and 9.4
± 5.2, respectively (p < 0.001). The mean anxiety
score for BODE stages I, II, III and IV was 5.9 ± 4.1,
FIGURE 1: BRONCHOALVEOLAR LAVAGE (BAL) CYTOLOGY
REVEALING SEVERE ATYPIA (PAPANICOLAU, 400x)
FIGURE 2: BRONCHOALVEOLAR LAVAGE (BAL) CYTOLOGY
SHOWING MILD ATYPIA (PAPANICOLAU, 400x)
TABLE I: CHARACTERISTICS OF THE PATIENTS    
Patient characteristics N (%)
Male/female  (%) 35/25 (58/42)
Age (years) 66 ± 11 
Pack-years 58 ± 28 
Current smoker (n) (%) 16 (26.7)
Body mass index, kg/m2 26 ± 4.5 
COPD duration (year) 7.45 ± 7.12 
LTOT use (n) (%) 10 (16.7)
NIMV use (n) (%) 5 (8.3)
Hospitalization in the previous year (n) (%) 12 (20)
FEV1, liters 1.3 ± 0.5 
FEV1 (%predicted) 51 ± 15
FVC, liters (%predicted) 2.7 ± 0.7 
FVC, %predicted 83 ± 14
FEV1/FVC 51 ± 15
pO2, mmHg 71.3 ± 9.7
pCO2, mmHg 39.8 ± 4.9
MRC dyspnea scale 2.2 ± 1.07
Six-minute walking distance 302 ± 120
BODE index 3.2 ± 2.5
Data are expressed as mean ± standard deviation (SD).
Definition of abbreviations: BODE, body mass, obstruction, dyspnea
and exercise capacity; COPD, chronic obstructive pulmonary disease;
FEV1, forced expiratory volume in one second; FVC, forced ventila-
tory capacity; LTOT, long term oxygen therapy; MRC, Medical
Research Council; NIMV, non-invasive mechanical ventilation. 
TABLE II: PATIENT CLASSIFICATION ACCORDING TO GOLD
AND BODE INDEXES    
Severity of COPD Patient number (%) BODE index
Stage II 30 (50%) 1 (1 to 4)
Stage III 20 (33.3%) 4 (3 to 6)
Stage IV 10 (16.7%) 7 (6 to 9)
Definition of abbreviations: BODE, body mass, obstruction, dyspnea
and exercise capacity; COPD, chronic obstructive pulmonary disease.
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8.2 ± 3.9, 9.7 ± 3.6 and 9.2 ± 5.3, respectively (p <
0.001). The mean depression score for BODE stages
I, II, III and IV was 5.2 ± 3.1, 6.8 ± 3.4, 9.4 ± 3.2
and 10.2 ± 4.6, respectively (p < 0.001). 
Sputum and BAL cytology results with regard to
anxiety and depression symptoms are shown in
Tables IV and V. Although the correlation of moder-
ate or severe cytologic atypia of sputum was not sta-
tistically significant for anxiety or depression symp-
toms, the specifity and sensitivity was found to be
67.2% and 68.4%, respectively (p < 0.05). The
prevalance of both anxiety and depression in-
creased with the increasing severity of cellular atyp-
ical findings of BAL cytology (χ2 = 20.36, p < 0.001;
χ2 = 9.46, p < 0.001). Moderate or severe atypical
changes of BAL cytology showed a significant cor-
relation with the anxiety and depression symptoms
with an 86% sensitivity and 89% specificity for
identifying their presence. The MMRC dyspnea in-
dex and 6MWD showed a significant correlation
with the increasing degree of atypical changes of
BAL cytology (β = 0.284, p < 0.002; 
β = 0.426, p < 0.001). MMRC dyspnea scale was
significantly associated both with the anxiety score
(β = 0.346, p < 0.023) and the depression score 
(β = 0.284, p < 0.042) while FEV1 % predicted did
not correlate with anxiety or depression score. 
DISCUSSION
COPD is considered not only as a disease of the
lungs but as a part of the chronic systemic inflam-
matory syndrome [1]. The complex pathogenesis of
COPD along with the associated frequent comor-
bidities compel further evaluation and staging be-
cause the degree of airflow obstruction is not ade-
quate on its own to fully describe this multicompos-
ite disease. Previous studies have revealed symp-
toms of anxiety and depression in up to 41% and
44% of COPD patients respectively [6,13]. Our re-
sults confirm that anxiety and depression symptoms
are common in COPD and may correlate with the
severity of the disease. Dyspnea due to the reduced
exercise capacity is probably the primary factor
leading to the psychiatric morbidities encountered
in our patients.
The degree of lung function impairment is not ade-
quate on its own to explain the presence of anxiety
and depression symptoms in COPD. Our findings
are in concordance with previous studies that
FEV1% predicted alone did not predict or correlate
with the presence of anxiety and depression symp-
toms [4,10,13]. Dyspnea and reduced exercise ca-
pacity which are indicators of advanced COPD cor-
related significantly with the presence of the anxiety
and depression symptoms. They may be predictive
of COPD outcomes. The BODE index was a better
predictor of the psychological impact of COPD
than the GOLD classification in regard to FEV1%
predicted.
COPD duration, number of yearly exacerbations,
and long term oxygen therapy (LTOT) did not corre-
late with anxiety and depression symptoms. There
was a weak correlation of depressive symptoms
with the noninvasive mechanical ventilation
(NIMV) treatment. Our findings verified that dys -
pnea correlated with the psychological conse-
quences of COPD. 
Another important aspect of our study is the associ-
ation between atypical changes in BAL cytology
with the anxiety and depression symptoms. As the
atypical changes of BAL cytology increased in
TABLE III: COMPARISON OF VARIOUS PARAMETERS WITH




Smoking (pack/years) 0,199 0,083
COPD stage 0,001 0,001
Disease duration (year) 0.078 0.086
Hospital admission 0.326 0.002




Definition of abbreviations: COPD, chronic obstructive pulmonary
disease; HAD, Hospital Anxiety and Depression scale; LTOT, long
term oxygen therapy; NIMV, non-invasive mechanical ventilation.
TABLE IV: DISTRIBUTION OF ANXIETY AND DEPRESSION ACCORDING TO SPUTUM CYTOLOGY CLASSIFICATION   
Sputum cytology: Number of patients Number of patients p
n. patients per group with anxiety symptoms (%) with depression symptoms (%)
N: 12 3 (25) 2 (16.6) < 0.36
MA: 16 5 (31.2) 6 (37.5) < 0.42
IA: 20 11 (55) 12 (60) < 0.062
SA: 12 7(58.3) 8 (66.6) < 0.067































severity, the prevalence of these symptoms grew
higher. This association may be explained by the
fact that BAL cytology reflects the structure of the
lung parenchyma. As the lung damage gets worse
the functional burden of dyspnea increases. Anxiety
and depression symptoms were best delineated by
dyspnea score and the 6-minute walking distance.
Worsening dyspnea affects physical conditioning
and produces functional limitation, as demonstrated
by the decreased 6MWD, which is probably the pre-
dominant mechanism leading to anxiety and depres-
sion symptoms in our patients. Patients whose exer-
cise capacity has been limited because of COPD
have the greatest risk of psychiatric comorbidities.
Atypical changes in sputum cytology were not sig-
nificantly associated with the presence of anxiety or
depression symptoms of COPD, while the sensitivi-
ty and specifity of sputum cytology for predicting
these symptoms was intermediate. We believe that
cytologic examination of sputum samples may be
useful for pointing out the psychiatric symptoms in
COPD patients. On the other hand, moderate or se-
vere cytologic findings of BAL were able to identify
psychiatric comorbidities of the disease. The high
correlation of atypical BAL cytology findings with
the presence of anxiety or depression symptoms we
attributed to the fact that BAL reflects the structure
of lung parenchyma. The significant correlation be-
tween the severity of the atypical findings of BAL
cytology and the MMRC index and the 6MWD
shows that the major risk factor for dyspnea and the
consequent functional physical limitation is the
severity of lung damage which may be identified by
BAL cytology. 
Our study included a mixture of males and females
at different GOLD stages. The small sample size of
our study may be considered as a disadvantage in
comparison to the other large prospective studies.
The HAD questionnaire used in this study may have
limitations in diagnosing anxiety and depression
but our patients were also evaluated by a consultant
psychiatrist. This questionnaire has been used suc-
cessfully in previous studies as a screening tool for
psychiatric morbidity [6,15]. We did not compare
the current psychiatric status of our patients after
psychiatric treatment and pulmonary rehabilitation
which may be another limitation of our study.
Pulmonary rehabilitation may have had an influ-
ence on this because the patients would feel better
and gain self-confidence vis-à-vis the functional
limitation due to the disease. In addition to the high
prevalence of respiratory symptoms, many of the
patients had anxiety and depression symptoms.
Cognitive and behavioral therapy, psychopharma-
cology and pulmonary rehabilitation may be useful
treatment modalities for psychyatric disorders in
COPD patients. 
We conclude that anxiety and depression symp-
toms are common in COPD. The psychological sta-
tus is important in these patients. Although there is
a clear association between dyspnea level and anx-
iety or depression symptoms, their presence is often
underdiagnosed and undertreated especially when
they coexist with physical illness [2,16]. The results
of our study suggest that the major risk factor for
anxiety or depression is dyspnea and the conse-
quent functional physical limitation. Cytologic ex-
amination of BAL cytology appears to be a useful
modality for identifying patients with psychiatric
comorbidities because it reflects the lung damage
which is the predominant mechanism underlying
dyspnea and the limited physical limitation of
COPD patients. BAL cytology can be used along
with the HAD index for screening COPD patients to
determine the presence of anxiety or depression
symptoms. Sputum cytology, in view of its borderline
significant association with and intermediate sensi-
tivity and specifity for anxiety and depression scores,
may be used as a noninvasive diagnostic tool for
identifying psychiatric comorbidities of COPD. 
CONFLICT OF INTEREST STATEMENT: None of the authors has
any conflict of interest to declare in relation to the subject
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TABLE V: DISTRIBUTION OF ANXIETY AND DEPRESSION SYMPTOMS ACCORDING TO BAL CYTOLOGY CLASSIFICATION   
BAL cytology: Number of patients Number of patients p
n. patients per group with anxiety symptoms (%) with depression symptoms (%)
N: 10 1 (10) 1 (10) < 0.42
MA: 16 3 (18.7) 4 (25) < 0.36
IA: 20 12 (60) 14 (70) < 0.05
SA: 14 10 (71.4) 11 (78.5) < 0.05
Definition of abbreviations: BAL, bronchoalveolar lavage; IA, intermediate atypia; MA, mild atypia; N, normal; SA, severe atypia. 
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